Data as of mid-2026
The longevity industry is legitimate as a scientific field and simultaneously carries a consumer marketing layer that is not. As of 2026 it has FDA-cleared human trials, published clinical data and institutional capital from sovereign wealth funds and national research agencies. It also has no approved drug that targets ageing itself,…
BUSINESS
By Unfiltered · Published August 2026 · Updated annually · Data as of mid-2026
The Unfiltered Longevity 100 ranks the 100 most influential people shaping the longevity industry in 2026 — investors, founders, scientists and influencers — each scored out of 100 across five weighted criteria. No. 1 is Hal Barron, CEO of Altos Labs;…
For a decade, the brain was where pharmaceutical money generally went to die. Too complex, too poorly understood, too many failed trials. Nicolas Roberti, co-founding partner of the European BrainTech Fund, calls it a graveyard.
His argument is that the graveyard is about to reopen for business, and that the reason is not a single…
Marc P. Bernegger started an internet company before the average person was online. He bought Bitcoin at $7. And he walked towards a little-known longevity expert at a conference after the man had said something so radical it caused members of the audience to walk out. That expert was the now-pioneering gerontologist Aubrey de Grey.…
Plenty of people have closed their eyes and had one a final throw of the dice in Vegas. Most of them walk away with nothing.
Tonight, Kristian Gkolomeev of Greece is going home with $1.25m after breaking the Men’s 50m Freestyle record, clocking 20.81 in the final event of the night at the inaugural Enhanced…
Longevity has stopped being a Silicon Valley curiosity. Over the past four years, the field has crossed the line from speculative science to institutional industry. Tech billionaires have poured billions into it. Sovereign wealth funds have arrived. The first human trial of partial cellular reprogramming starts this year, with FDA clearance already in hand. A…
Bret Kovacs commutes several hours a day into New York. Most mornings he stands on the same train platform looking at the same set of ads. Hims, Ro and the rotating cast of consumer health brands competing for the same eye-line. The visual grammar is consistent: vials, syringes and pills. Sometimes a model. Sometimes a…
Stefan Eckhardt doesn't think much of pitch decks. He'd rather get a well-written email. And when a working prototype arrives in a founder meeting, what interests him isn't what it does — it's what it tells him about how the founders think.
Eckhardt is managing director of Callisto Health, the Berlin-based health-tech investor that led…
If you had to design the person you'd want on your side if you were an athlete about to walk into the most scrutinised sporting arenas of the modern era, you'd probably end up with someone who looked a lot like Rick Adams.
Six Olympic Games. Fourteen years inside the American Olympic machine. Former Chief…
The conference is in full swing when Kim Oreskovic admits she doesn't wear a smartwatch. It's the second day of the Health Tech Global Summit in Basel, March 2026, and the floor outside the room is humming of founders selling the opposite case: rings, patches, breath analysers, blood-test interpreters, all promising that more data will…



